39 related articles for article (PubMed ID: 38581990)
1. PAK1 inhibition increases TRIM21-induced PD-L1 degradation and enhances responses to anti-PD-1 therapy in pancreatic cancer.
Wang K; Yan L; Qiu X; Chen H; Gao F; Ge W; Lian Z; Wei X; Wang S; He H; Xu X
Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167236. PubMed ID: 38740225
[TBL] [Abstract][Full Text] [Related]
2. Exploring in vivo combinatorial chemo-immunotherapy: Addressing p97 suppression and immune reinvigoration in pancreatic cancer with tumor microenvironment-responsive nanoformulation.
Lo YL; Li CY; Chou TF; Yang CP; Wu LL; Chen CJ; Chang YH
Biomed Pharmacother; 2024 Jun; 175():116660. PubMed ID: 38701563
[TBL] [Abstract][Full Text] [Related]
3. Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1-Specific VHHs.
Dougan M; Ingram JR; Jeong HJ; Mosaheb MM; Bruck PT; Ali L; Pishesha N; Blomberg O; Tyler PM; Servos MM; Rashidian M; Nguyen QD; von Andrian UH; Ploegh HL; Dougan SK
Cancer Immunol Res; 2018 Apr; 6(4):389-401. PubMed ID: 29459478
[TBL] [Abstract][Full Text] [Related]
4. A Histone Methylation-MAPK Signaling Axis Drives Durable Epithelial-Mesenchymal Transition in Hypoxic Pancreatic Cancer.
Brown BA; Myers PJ; Adair SJ; Pitarresi JR; Sah-Teli SK; Campbell LA; Hart WS; Barbeau MC; Leong K; Seyler N; Kane W; Lee KE; Stelow E; Jones M; Simon MC; Koivunen P; Bauer TW; Stanger BZ; Lazzara MJ
Cancer Res; 2024 Jun; 84(11):1764-1780. PubMed ID: 38471099
[TBL] [Abstract][Full Text] [Related]
5. Long-term combined blockade of CXCR4 and PD-L1 with in vivo reassembly for intensive tumor interference.
Deng ZW; Yang JK; Qiu KJ; Zhang TJ; He Z; Wang N; Chen XG; Liu Y
J Control Release; 2024 Jun; 370():453-467. PubMed ID: 38697315
[TBL] [Abstract][Full Text] [Related]
6. Nanodiamond Mediated Molecular Targeting in Pancreatic Ductal Adenocarcinoma: Disrupting the Tumor-stromal Cross-talk, Next Hope on the Horizon?
Singh M; Pal P; Dutta RS; Marbaniang D; Ray S; Mazumder B
Curr Cancer Drug Targets; 2023; 23(8):620-633. PubMed ID: 36843367
[TBL] [Abstract][Full Text] [Related]
7. Cellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC.
Musiu C; Lupo F; Agostini A; Lionetto G; Bevere M; Paiella S; Carbone C; Corbo V; Ugel S; De Sanctis F
Front Immunol; 2024; 15():1341079. PubMed ID: 38817612
[TBL] [Abstract][Full Text] [Related]
8. Enhancing Tumor Immunotherapy by Multivalent Anti-PD-L1 Nanobody Assembled via Ferritin Nanocage.
Liu M; Jin D; Yu W; Yu J; Cao K; Cheng J; Zheng X; Wang A; Liu Y
Adv Sci (Weinh); 2024 May; 11(20):e2308248. PubMed ID: 38491904
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Strategies for Pancreatic-Cancer-Related Type 2 Diabetes Centered around Natural Products.
Park MN
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958889
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target.
Hartupee C; Nagalo BM; Chabu CY; Tesfay MZ; Coleman-Barnett J; West JT; Moaven O
Front Immunol; 2024; 15():1287459. PubMed ID: 38361931
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4.
Zeng J; Fang Y; Zhang Z; Lv Z; Wang X; Huang Q; Tian Z; Li J; Xu W; Zhu W; Yu J; Liu T; Qian Q
Oncogene; 2024 May; ():. PubMed ID: 38806619
[TBL] [Abstract][Full Text] [Related]
12. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
13. IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.
Imai D; Yoshizumi T; Okano S; Itoh S; Ikegami T; Harada N; Aishima S; Oda Y; Maehara Y
J Surg Res; 2019 Aug; 240():115-123. PubMed ID: 30927618
[TBL] [Abstract][Full Text] [Related]
14. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
Fu Y; Liu S; Zeng S; Shen H
Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
[TBL] [Abstract][Full Text] [Related]
15. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
16. The nanobody targeting PD-L1 and CXCR4 counteracts pancreatic stellate cell-mediated tumour progression by disrupting tumour microenvironment.
Li Y; Zheng Y; Xu S; Hu H; Peng L; Zhu J; Wu M
Int Immunopharmacol; 2024 May; 132():111944. PubMed ID: 38581990
[TBL] [Abstract][Full Text] [Related]
17. Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4.
Hao S; Xu S; Li L; Li Y; Zhao M; Chen J; Zhu S; Xie Y; Jiang H; Zhu J; Wu M
BMC Cancer; 2022 Oct; 22(1):1092. PubMed ID: 36284271
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
